Thrombosis Research
Volume 121, Issue 3 , Pages 339-345 , 2007

Associations of the β-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis

  • Mary Cushman

      Affiliations

    • Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
    • Corresponding Author InformationCorresponding author. Department of Medicine, University of Vermont, 208 South Park Drive, Suite 2, Colchester, VT 05446, USA. Tel.: +1 802 656 8968; fax: +1 802 656 8965.
    • ,
  • Alexandra Cornell

      Affiliations

    • Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
    • ,
  • Aaron R. Folsom

      Affiliations

    • Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA
    • ,
  • Lu Wang

      Affiliations

    • Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
    • ,
  • Michael Y. Tsai

      Affiliations

    • Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA
    • ,
  • Joseph Polak

      Affiliations

    • Department of Radiology, New England Medical Center, Boston, MA, USA
    • ,
  • Zhonghua Tang

      Affiliations

    • Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA, USA

Received 2 April 2007 ,Revised 9 May 2007 ,Accepted 14 May 2007.

References 

  1. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood. 1999;93:906–908
  2. Franco RF, Reitsma PH, Lourenco D, Maffei FH, Morelli V, Tavella MH, et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost. 1999;81:676–679
  3. Balogh I, Szoke G, Karpati L, Wartiovaara U, Katona E, Komaromi I, et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood. 2000;96:2479–2486
  4. Margaglione M, Bossone A, Brancaccio V, Ciampa A, Di Minno G. Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis. Thromb Haemost. 2000;84:1118–1119
  5. van Hylckama Vlieg A, Komanasin N, Ariens RA, Poort SR, Grant PJ, Bertina RM, et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol. 2002;119:169–175
  6. Salazar-Sanchez L, Leon MP, Cartin M, Schuster G, Wulff K, Schroder W, et al. The FXIIIVal34Leu, common and risk factors of venous thrombosis in early middle-age Costa Rican patients. Cell Biochem Funct. 2006;
  7. Wells PS, Anderson JL, Scarvelis DK, Doucette SP, Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol. 2006;164:101–109
  8. Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem. 2000;275:20627–20631
  9. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I, et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost. 2000;84:595–600
  10. Schroder V, Kohler HP. Effect of factor XIII Val34Leu on alpha2-antiplasmin incorporation into fibrin. Thromb Haemost. 2000;84:1128–1130
  11. Vossen CY, Rosendaal FR. The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J Thromb Haemost. 2005;3:1102–1103
  12. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet. 2003;361:1424–1431
  13. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case–control study of plasma levels and DNA polymorphisms — the Leiden Thrombophilia Study (LETS). Thromb Haemost. 1994;71:719–722
  14. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517–1532
  15. Austin H, Hooper WC, Lally C, Dilley A, Ellingsen D, Wideman C, et al. Venous thrombosis in relation to fibrinogen and factor VII genes among African–Americans. J Clin Epidemiol. 2000;53:997–1001
  16. Renner W, Cichocki L, Forjanics A, Koppel H, Gasser R, Pilger E. G-455A polymorphism of the fibrinogen beta gene and deep vein thrombosis. Eur J Clin Invest. 2002;32:755–758
  17. Bozic M, Teran N, Peterlin B, Stegnar M. Fibrinogen polymorphisms TaqI, HaeIII and BclI are not associated with a higher risk of deep vein thrombosis. Pathophysiol Haemost Thromb. 2003;33:164–169
  18. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113:636–642
  19. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003;1:2677–2678
  20. Carter AM, Mansfield MW, Stickland MH, Grant PJ. Beta-fibrinogen gene −455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care. 1996;19:1265–1268
  21. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation. 1996;93:440–449
  22. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology. Am J Med. 2004;117:19–25
  23. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263–276
  24. The Atherosclerosis Risk in Communities (ARIC) . Study: design and objectives. Am J Epidemiol. 1989;129:687–702
  25. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, et al. Prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 2002;99:2720–2725
  26. Chambless L, McMahon R, Finch A, Sorlie P, Heiss G, Lyles R, et al. ARIC Hemostasis Study-III. Quality control. Thromb Haemost. 1993;70:588–594
  27. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;42:264–270
  28. Alhenc-Gelas M, Reny JL, Aubry ML, Aiach M, Emmerich J. The FXIII Val 34 Leu mutation and the risk of venous thrombosis. Thromb Haemost. 2000;84:1117–1118
  29. Rasumussen-Torvik L, Cushman M, Tsai MY, Zhang Y, Heckbert SR, Rosamond WD, et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the longitudinal investigation of venous thromboembolism study. Thromb Res in press.

PII: S0049-3848(07)00214-9

doi: 10.1016/j.thromres.2007.05.009

Thrombosis Research
Volume 121, Issue 3 , Pages 339-345 , 2007

Article Tools